- AbbVie Inc (NYSE:ABBV) announced primary results from the large B-cell lymphoma (LBCL) expansion cohort in the EPCORE NHL-1 phase 2 trial of epcoritamab.
- Epcoritamab demonstrated efficacy with durable responses in patients who had previously received at least two prior lines of anti-lymphoma therapy.
- The study cohort, which included 157 relapsed/refractory LBCL patients, demonstrated an overall response rate (ORR) of 63% and a complete response (CR) rate of 39%.
- Related: AbbVie - Genmab Post Epcoritamab Data From Early-Stage Blood Cancer Study.
- Patients in the study who were naïve to CAR T-cell therapy achieved a 69% ORR and a 42% CR, and patients who received prior CAR T-cell therapy achieved a 54% ORR and a 34% CR.
- After a median follow-up of 10.7 months, the median duration of response (mDOR) was estimated to be 12 months, while the mDOR among patients achieving a CR was not reached, with 89% still in CR at nine months.
- Epcoritamab is being co-developed by AbbVie and Genmab A/S (NASDAQ:GMAB) as part of the companies' broad oncology collaboration.
- Price Action: ABBV shares are down 1.42% at $141.11, and GMAB is down 3.18% at $27.97 during the market session on the last check Monday.
